TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19174792

Group type: EXPERIMENTAL
Intervention: VSL#3 (450‐1,800 billion bacteria/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 29
Study: 17557453

Group type: EXPERIMENTAL
Intervention: eszopiclone 3 mg (cotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo (monotherapy)
Number of subjects: 0
Study: 15805382

Group type: EXPERIMENTAL
Intervention: Standard 2-dose regimen of TIV administered in the fall
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Early schedule of a single spring dose followed by a fall dose of TIV
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: TIV with concomitant vaccines
Number of subjects: 259

Group type: COMPARATOR
Intervention: TIV (both groups)
Number of subjects: 259
Study: 12087544

Group type: EXPERIMENTAL
Intervention: Bleaching treatments (various concentrations) for 7 or 14 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (water instead of bleaching gel)
Number of subjects: 63
Study: 9854805

Group type: EXPERIMENTAL
Intervention: PDA (Personal Digital Assistant)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Computer
Number of subjects: 136

Group type: COMPARATOR
Intervention: Paper method
Number of subjects: 136
Study: 7896983

Group type: EXPERIMENTAL
Intervention: Behavior skills training HIV-risk reduction intervention (6 sessions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard HIV education
Number of subjects: 34
Study: 2694604

Group type: EXPERIMENTAL
Intervention: 250, 500, or 1,000 mg/kg of IVIG plus antibiotics
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 30
Study: 820104

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (5 mg)
Number of subjects: 20
Study: 30500086

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 74

Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 74
Study: 28030534

Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*3 allele
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 and CYP3A5*1/*3 carrier subgroups
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients younger than 10 years
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients off steroids
Number of subjects: 37
Study: 25537522

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPS) intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study: 23817002

Group type: EXPERIMENTAL
Intervention: Mepitel One (soft silicone wound contact layer)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bridal Veil and staples
Number of subjects: 43
Study: 21563503

Group type: EXPERIMENTAL
Intervention: Jingyuankang capsule
Number of subjects: 58

Group type: COMPARATOR
Intervention: Leucogen tablet
Number of subjects: 58
Study: 19290019

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: NORM (age-matched controls without a cancer diagnosis)
Number of subjects: 86
Study: 16773343

Group type: EXPERIMENTAL
Intervention: Clinical investigation course for surgeons
Number of subjects: 24
Study: 15070006

Group type: EXPERIMENTAL
Intervention: Individuals with TBI
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 18
Study: 11242482

Group type: EXPERIMENTAL
Intervention: Modified sham feeding a low-fat meal (6 g fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified sham feeding a moderate-fat meal (38 g fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 10
Study: 9287227

Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Zidovudine and lamivudine alone
Number of subjects: 1156
Study: 8420235

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 29128975

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study: 27089045

Group type: EXPERIMENTAL
Intervention: Emotional support coping
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Acceptance coping
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Denial coping
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Self‐blame coping
Number of subjects: 350
Study: 24919564

Group type: EXPERIMENTAL
Intervention: MEND intervention (Mind, Exercise, Nutrition..Do it!) for childhood overweight or obesity, 10 weeks duration, 2 sessions/week.
Number of subjects: 21932
Study: 23387822

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activator [t‐PA], mechanical clot disruption or retrieval, or a combination of these approaches)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Intravenous t‐PA
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 362
Study: 19633060

Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) plus Routine Clinical Care (RCC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC) alone
Number of subjects: 94
Study: 18761238

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg bolus, 0.05 microg/kg per min infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl (1 microg/kg bolus, 0.5 microg/kg bolus doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study: 16471102

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV administered twice
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tramadol 50 mg IV administered twice
Number of subjects: 50
Study: 12939421

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day (after 5 mg/day for the first 28 days)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 10481525

Group type: EXPERIMENTAL
Intervention: Immunofluorescence with MAC‐1, MAC‐31, NSE and anti‐Fucosyl‐GM1 (PF3) antibodies
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (5 patients with other malignancies)
Number of subjects: 32
Study: 8784635

Group type: EXPERIMENTAL
Intervention: Timolol maleate (one drop at the end of surgery) in the NG-T group
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment in the NG group
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment in the G group
Number of subjects: 39
Study: 1810999

Group type: EXPERIMENTAL
Intervention: Dibenzoylmethane derivatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dibenzoylmethane derivative and physical agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical agents
Number of subjects: 0
Study: 6925982

Group type: EXPERIMENTAL
Intervention: Single intrapleural injection of BCG
Number of subjects: 118

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 118
Study: 31823462

Group type: EXPERIMENTAL
Intervention: Cervical cancer screening participation
Number of subjects: 2408

Group type: EXPERIMENTAL
Intervention: Age, social status, knowledge of cervical cancer screening, and baseline screening outcome
Number of subjects: 2408
Study: 29777003

Group type: EXPERIMENTAL
Intervention: Aducanumab (1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aducanumab (3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aducanumab (6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aducanumab (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28895777

Group type: EXPERIMENTAL
Intervention: Facilitatory KT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inhibitory KT
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham KT
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untaped condition
Number of subjects: 33
Study: 24682319

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 120
Study: 24768239

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 666

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 666
Study: 22476230

Group type: EXPERIMENTAL
Intervention: Candesartan treatment (+ thiazide diuretics)
Number of subjects: 310
Study: 19235080

Group type: EXPERIMENTAL
Intervention: Web-based intervention with loss frame messaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based intervention with gain frame messaging
Number of subjects: 0
Study: 18410608

Group type: EXPERIMENTAL
Intervention: Combination therapy of Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lamivudine monotherapy continuously
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination therapy of Talpha1 and lamivudine
Number of subjects: 67
Study: 15752410

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with caudal catheter placement (AD group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Epidural anesthesia with cephalad catheter placement (AU group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with caudal catheter placement (HD group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Epidural anesthesia with cephalad catheter placement (HU group)
Number of subjects: 42
Study: 12016348

Group type: EXPERIMENTAL
Intervention: Magnetic field treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard medication (diclofenac and tizanidine)
Number of subjects: 192
Study: 10463630

Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8830065

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg per day for 8 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2337035

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35196

Group type: EXPERIMENTAL
Intervention: Clobazam (10-60 mg daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Clobazam (49 mg daily)
Number of subjects: 11
Study: 31216852

Group type: EXPERIMENTAL
Intervention: Palliative systemic therapy
Number of subjects: 126
Study: 28674122

Group type: EXPERIMENTAL
Intervention: Culturally targeted lifestyle intervention (individual counselling using motivational interviewing, family session, cooking classes, supervised physical activity programme)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Generic lifestyle advice (control group)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Culturally targeted lifestyle intervention
Number of subjects: 536
Study: 26510728

Group type: EXPERIMENTAL
Intervention: Younger children (aged <12 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescents (aged 12-18 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adults
Number of subjects: 0
Study: 23242758

Group type: EXPERIMENTAL
Intervention: Bacterial lysate (Escherichia coli and Enterococcus faecalis), prophylactic treatment for 26 weeks
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 20554358

Group type: EXPERIMENTAL
Intervention: Antegrade dissection (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrograde dissection (n=20)
Number of subjects: 40
Study: 19292625

Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17923543

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (2.5 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 62
Study: 15314546

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (3 x 10(6) IU/m2/day) administered daily for 6 weeks with a weekly melanoma peptide vaccine.
Number of subjects: 40
Study: 11332212

Group type: EXPERIMENTAL
Intervention: Vaginal administration of 1 mg gemeprost (group 2A, n: 17)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Surgical management (curettage, group 2B, n: 17)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Expectancy management (group 1, n: 27)
Number of subjects: 61
Study: 9329410

Group type: EXPERIMENTAL
Intervention: Heparin (1 unit per milliliter in umbilical catheter infusate)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No heparin (control group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Antenatal indomethacin use
Number of subjects: 113
Study: 7942578

Group type: EXPERIMENTAL
Intervention: Fish oil enriched in omega-3 fatty acids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vegetable oil enriched in oleic acid
Number of subjects: 20
Study: 3357072

Group type: EXPERIMENTAL
Intervention: Intervention involving lecture, feedback, and checklists during ambulatory care rotation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (residents not exposed to the program)
Number of subjects: 28
Study: 30043885

Group type: EXPERIMENTAL
Intervention: Brief intervention (BrInter, n = 45)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intensive intervention with presentation of an educational video (InInterV, n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 90

Group type: COMPARATOR
Intervention: Craving (moderate or intense)
Number of subjects: 90
Study: 28271943

Group type: EXPERIMENTAL
Intervention: Talus Control Foot Orthoses (TCFOs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rigid Foot Orthoses (RFOs)
Number of subjects: 40
Study: 26174571

Group type: EXPERIMENTAL
Intervention: Non-splint multimodal therapy plus stabilisation splint (NS+S)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Non-splint multimodal therapy (NS)
Number of subjects: 181
Study: 24093846

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Triple therapy (TT)
Number of subjects: 304
Study: 21167565

Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization of bladder tumors (BPV-BT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of bladder tumors (TURBT)
Number of subjects: 120
Study: 19597412

Group type: EXPERIMENTAL
Intervention: Polyglucosamine (PG) 2 g/day
Number of subjects: 30
Study: 17357520

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diltiazem+SNP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: labetalol+SNP
Number of subjects: 60
Study: 14572565

Group type: EXPERIMENTAL
Intervention: 6.5-h infusion of gabexate (500 mg total)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: 13-h infusion of gabexate (1 g total)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 434
Study: 10629468

Group type: EXPERIMENTAL
Intervention: 2-component acellular pertussis vaccine (APV) composed of pertussis toxin and filamentous hemagglutinin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Meningococcal vaccine (control)
Number of subjects: 100
Study: 8959467

Group type: EXPERIMENTAL
Intervention: Ethanol (0.55 g/kg of body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 10
Study: 1326741

Group type: EXPERIMENTAL
Intervention: D x RRV vaccine (10^4 plaque-forming units/1-ml dose)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: DS 1 x RRV vaccine (10^5 plaque-forming units/1-ml dose)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 359
Study: 4048752

Group type: EXPERIMENTAL
Intervention: Cefoperazone (2 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ampicillin (6 g/d) + Tobramycin (3 to 4 mg/kg/d)
Number of subjects: 30
Study: 29553834

Group type: EXPERIMENTAL
Intervention: 2% dill vaginal suppositories
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100 mg clotrimazole vaginal tablets
Number of subjects: 60
Study: 27999313

Group type: EXPERIMENTAL
Intervention: Preterm infant, post‐discharge nutrition (PIN) program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional nutrition services
Number of subjects: 22
Study: 24115072

Group type: EXPERIMENTAL
Intervention: ONO-5334 immediate release tablet (IRT)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: ONO-5334 sustained release tablet (SRT)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Caucasian subjects
Number of subjects: 295

Group type: COMPARATOR
Intervention: Japanese subjects
Number of subjects: 295
Study: 20973828

Group type: EXPERIMENTAL
Intervention: Eccentric elbow flexor exercise
Number of subjects: 0
Study: 20151971

Group type: EXPERIMENTAL
Intervention: UK-369,003 (10, 25, 50 or 100 mg once a day for 12 weeks)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: UK-369,003 (in subset with ED)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo (in subset with ED)
Number of subjects: 310
Study: 18201612

Group type: EXPERIMENTAL
Intervention: 10% activated PRP (0.38x increase in platelet count)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 25% activated PRP (0.95x increase in platelet count)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Activated PRP (10% and 25%)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Nonactivated PRP
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (without PRP)
Number of subjects: 1
Study: 16437657

Group type: EXPERIMENTAL
Intervention: 5‐ASA (50 mg/kg/d) + omega‐3 FAs (3 g/d, EPA 400 mg/g, DHA 200 mg/g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 5‐ASA (50 mg/kg/d) + olive oil placebo capsules
Number of subjects: 38
Study: 12706010

Group type: EXPERIMENTAL
Intervention: Computed tomography osteoabsorptiometry in cuff tear shoulders
Number of subjects: 19

Group type: COMPARATOR
Intervention: Computed tomography osteoabsorptiometry in normal shoulders
Number of subjects: 19
Study: 10753002

Group type: EXPERIMENTAL
Intervention: Metrifonate 30-60 mg
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Metrifonate 60/80 mg
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1277
Study: 8604957

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and Placebo
Number of subjects: 70
Study: 1421640

Group type: EXPERIMENTAL
Intervention: Heparin sodium 1000 units/mL
Number of subjects: 81

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 81
Study: 6399890

Group type: EXPERIMENTAL
Intervention: Oral frusemide/amiloride combination tablet (40 mg frusemide and 5 mg amiloride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially-available 40 mg frusemide tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercially-available 5 mg amiloride tablets
Number of subjects: 12
Study: 31033190

Group type: EXPERIMENTAL
Intervention: Metoprolol treatment in PEAR-2 study
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Atenolol treatment in PEAR study
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Atenolol add-on cohort
Number of subjects: 434
Study: 30397007

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at 'four sacral points' along with routine medical care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional electroacupuncture along with routine medical care
Number of subjects: 140
Study: 27736850

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Postnatal recruitment
Number of subjects: 1806
Study: 24511022

Group type: EXPERIMENTAL
Intervention: S-1 plus irinotecan (SIri)
Number of subjects: 102

Group type: COMPARATOR
Intervention: S-1 plus paclitaxel (SPac)
Number of subjects: 102
Study: 22892323

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day + statin
Number of subjects: 150

Group type: COMPARATOR
Intervention: double-dose statin
Number of subjects: 150
Study: 20181994

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 213
Study: 17673615

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study: 11281486

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g intravenously after induction of anesthesia (PA group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (NONE group)
Number of subjects: 102
Study: 9374260

Group type: EXPERIMENTAL
Intervention: Polyacrylic acid 0.2% (PAA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Polyvinylalcohol 1.4% (PVA)
Number of subjects: 85
Study: 8338261

Group type: EXPERIMENTAL
Intervention: 35 ml of 1.5% lidocaine with 1 in 200,000 of adrenaline (Group A)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1 microgram.kg‐1 of fentanyl with the same dose of lidocaine (Group B)
Number of subjects: 13
Study: 3525976

Group type: EXPERIMENTAL
Intervention: Antazoline (Antistine) in addition to conventional immunosuppressive therapy (group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional immunosuppressive therapy only (group B)
Number of subjects: 69
Study: 31665935

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 487

Group type: COMPARATOR
Intervention: Dexamethasone 0.7 mg implant
Number of subjects: 487
Study: 28224313

Group type: EXPERIMENTAL
Intervention: Black gay male stereotypes
Number of subjects: 285

Group type: COMPARATOR
Intervention: Stereotypes of Black men
Number of subjects: 285

Group type: COMPARATOR
Intervention: Stereotypes of gay men
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Unique stereotypes of Black MSM
Number of subjects: 285